Patents Represented by Attorney Licata & Tyrrell P.C.
  • Patent number: 8105593
    Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: January 31, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gene Kinney, William R. Strohl, Zhiqiang An
  • Patent number: 8088728
    Abstract: The present invention provides methods for the local treatment of acute and chronic extravascular pulmonary fibrin deposition and/or reducing unwanted effects associated with systemic administration of natural anticoagulants to a subject via airway administration to the subject by intratracheal, intrabronchial or intraalveolar routes of natural anticoagulants or biologically active derivatives thereof.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: January 3, 2012
    Assignee: Drugrecure APS
    Inventor: Lars Otto Uttenthal
  • Patent number: 8088886
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Grant
    Filed: April 2, 2003
    Date of Patent: January 3, 2012
    Assignee: Smith-Kline Beecham P.L.C.
    Inventors: Colin Houston MacPhee, David Graham Tew
  • Patent number: 8084217
    Abstract: The invention relates to a CD161 ligand known as Proliferation-Induced Lymphocyte-Associated Receptor (PILAR), which is crucial for a robust expansion of human lymphocytes. PILAR is markedly up-regulated on both CD4 and CD8 T cells upon TCR engagement and increases the expression of anti-apoptotic genes and glucose transporters through CD161, which globally results in a dramatic enhancement of T cell proliferation. Agents which stimulate or block this activity are also provided as are methods for manipulating PILAR signaling in the treatment of disease.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: December 27, 2011
    Assignee: Trustees of Dartmouth College
    Inventors: Jose R. Conejo-Garcia, Eduardo Huarte-Sobrino, Juan Cubillos-Ruiz, Yolanda Nesbeth, Diana G. Martinez
  • Patent number: 8080650
    Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: December 20, 2011
    Assignee: diaDexus, Inc.
    Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
  • Patent number: 8071533
    Abstract: Compositions and methods for modulating activity of store-operated calcium entry in cells or tissues are provided. The compositions comprise the P311 protein, fused to a cell-penetrating peptide and formulated for delivery to tissues and cells. This protein has been shown to increase the levels of store-operated calcium entry (SOCE) in gingival cells, skeletal muscle cells, and prostate epithelial cells. Also provided are methods for preventing and treating diseases that involve administration of the P311 fusion protein, as well as methods for increasing levels of SOCE in cells.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: December 6, 2011
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Jianjie Ma, Noah Weisleder, Zui Pan
  • Patent number: 8067389
    Abstract: The present application is directed to siRNA-based silencing of the type II receptor of TGF?. siRNAs that target this receptor abrogate the receptor protein and transcript, TGF?-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGF? type II receptor level and modulate wound response. Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: November 29, 2011
    Assignee: The Broad of Trustees of the University of Illinois
    Inventors: Nalin M. Kumar, Beatrice Yue, Shahid Siddiqui, Asrar B. Malik, Jose S. Pulido
  • Patent number: 8067583
    Abstract: The present invention is a method for synthesizing furanosteroids. The method involves intramolecular Diels-Alder/retro-Diels-Alder reaction and tautomerization of a functionalized alkyne oxazole to produce a furo[2,3-b]phenol derivative which is elaborated by intermolecular and intramolecular condensations to generate ring-A of the furanosteroid. Furanosteroids and pharmaceutical compositions containing the same are also provided.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: November 29, 2011
    Assignee: Trustees of Dartmouth College
    Inventor: Peter A. Jacobi
  • Patent number: 8068898
    Abstract: This invention relates to method and apparatus for collection of the complete fluorescence emission spectrum and the transient decay of a selected spectral band simultaneously with data acquisition times of less that one second. This invention is useful for studying human tissues and cells in vivo.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: November 29, 2011
    Assignee: Trustees of Dartmouth College
    Inventors: Mary-Ann Mycek, Ethan Dmitrovsky, Jonathan Pitts
  • Patent number: 8053413
    Abstract: The present invention relates to a method for preventing or ameliorating a sleep-related breathing disorder. The method involves the use of one or a combination of cholecystokinin (CCK) receptor antagonists.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: November 8, 2011
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: David W. Carley, Miodrag Radulovacki
  • Patent number: 8034368
    Abstract: The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: October 11, 2011
    Assignee: Innocoll Technologies Limited
    Inventors: Michael Myers, Philip Wallace Reginald
  • Patent number: 8029787
    Abstract: The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: October 4, 2011
    Assignee: diaDexus, Inc.
    Inventors: Susana Salceda, Yongming Sun, Herve Recipon, Robert Cafferkey
  • Patent number: 8029770
    Abstract: The present invention relates to pharmaceutical compositions containing a caffeine salt complex and a pharmaceutically acceptable carrier for use in methods for preventing or treating cancer or solar dermatitis. Methods for inducing apoptosis or inhibiting proliferation in a cancer cell or cell which as UVB-induced DNA damage using a caffeine salt complex or methylated xanthine are also provided.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: October 4, 2011
    Assignee: Rutgers, The State University
    Inventors: Yaoping Lu, Allan H. Conney, YouRong Lou
  • Patent number: 8030446
    Abstract: The present invention relates to mutant proline-and-arginine rich (PR) peptides with defined structural characteristics for use in inhibiting mammalian 20S proteasome activity and modulating expression of genes regulating the NF-?B pathway. Mutant PR peptides of the present invention differ from wild-type PR peptides by having at least one to three amino acid substitutions, wherein at least one of the amino acid residues at position one, two or three of the mutant PR peptide is positively charged.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: October 4, 2011
    Assignees: Trustees of Dartmouth College, Board of Regents University of Texas System
    Inventors: Sudha Veeraraghavan, Michael Simons
  • Patent number: 8030027
    Abstract: The present invention is a method for enhancing recombinant antibody production by co-expressing in a host cell a recombinant antibody and ERp23 protein, which facilitates oxidative folding and stability of the recombinant antibody thereby enhancing production.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: October 4, 2011
    Assignee: St. Jude Children's Research Hospital
    Inventors: Yuichiro Shimizu, Linda M. Hendershot
  • Patent number: 8017161
    Abstract: Methods for use of a composition comprising Bowman-Birk Inhibitor (BBI) or a derivative thereof in the treatment and/or prevention of skeletal muscle atrophy, to improve of skeletal muscle function, and to alleviate symptoms and/or slow progression of degenerative skeletal muscle diseases or disorders are provided.
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: September 13, 2011
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: H. Lee Sweeney, Carl A. Morris, Ann R. Kennedy
  • Patent number: 8011625
    Abstract: This invention relates to novel “bracket” to be used in the operating room of hospitals. The bracket of the invention holds a transducer at the level of a patient's heart in order to easily and accurately record pressures during surgery.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: September 6, 2011
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventor: Steven H. Ginsberg
  • Patent number: D646320
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: October 4, 2011
    Inventor: Samuel Chris Perks
  • Patent number: D650005
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: December 6, 2011
    Inventor: Samuel Chris Perks
  • Patent number: D650006
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: December 6, 2011
    Inventor: Samuel Chris Perks